BCDA
BioCardia Seizes Momentum in Q1 2026 with Groundbreaking CardiAMP Cell Therapy Results
BioCardia, a pioneering biotechnology company, has achieved significant milestones in its first quarter of 2026. Driven by the impressive results from its CardiAMP cell therapy for treating ischemic heart failure, the company has made substantial progress towards regulatory approval and commercialization. Speaking on the Q1 2026 conference call, BioCardia'